MIKA Pharma GmbH started its research on transcutaneous delivery in the 1990s and was the first company worldwide to develop a stable topical liposomal product in the pharmaceutical field (the liposomal MIKA-heparin-spray). Further extensive investigations led MIKA Pharma GmbH to develop even more favorable drug delivery systems on the basis of highly innovative proprietary and special microemulsions, and later even brand new nanoemulsions.